Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Director departure
Acq. announced
Inv. presentation
Filed Chapter 11
Codiak BioSciences, Inc. (CDAK) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/04/2022 8-K Quarterly results
05/05/2022 8-K Quarterly results
03/10/2022 8-K Quarterly results
11/04/2021 8-K Quarterly results
Docs: "Codiak BioSciences Reports Third Quarter 2021 Financial Results and Recent Operational Progress"
08/05/2021 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report August 5, 2021 Codiak BioSciences, Inc. Delaware 001-39615 47-4926530 35 CambridgePark Drive, Suite 500 Cambridge, MA 02140 949-4100 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communications pursuant to Rule 13e-4 under the E...",
"Codiak BioSciences Reports Second Quarter 2021 Financial Results and Operational Progress"
05/06/2021 8-K Quarterly results
03/17/2021 8-K Quarterly results
11/20/2020 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report November 19, 2020 Codiak BioSciences, Inc. Delaware 001-39615 47-4926530 35 CambridgePark Drive, Suite 500 Cambridge, MA 02140 949-4100 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communications pursuant to Rule 13e-4 under th...",
"Codiak BioSciences Reports Third Quarter 2020 Financial Results and Operational Progress"

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy